The future of heart drug research in the wake of study setbacks
On this week’s episode of “The Readout LOUD”: the failure of two closely followed heart disease drugs and how these setbacks may impact the future of cardiovascular drug research.
- Plus, drug safety concerns weigh on some of the biggest companies in the sector.
But then came this year’s American Heart Association meeting, which was dominated by presentations of clinical trials that showed no benefit whatsoever for two drugs long thought to be genetically validated.
For years, it was widely believed that a deeper understanding of genetics was going to speed the development of newer and better medicines for patients with heart disease.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →